Gene | Associated with JUVENILE MYELOMONOCYTIC LEUKEMIA in | Link to HGNC | Cytogenetic band | Number of associated diseases | Associated diseases |
---|---|---|---|---|---|
SETBP1 | HUMSAVAR | HGNC link | 18q12.3 | 6 | 601626, 614286, 608232, 269150, PS156200, 607785 |
PTPN11 | ClinVar, OMIM, HUMSAVAR | HGNC link | 12q24.13 | 4 | PS163950, 607785, 156250, PS151100 |
NRAS | ClinVar, HUMSAVAR | HGNC link | 1p13.2 | 8 | 137550, PS163950, 249400, 163200, 607785, 114500, 614470, 162900 |
CBL | ClinVar | HGNC link | 11q23.3 | 2 | 607785, 613563 |
MLLT11 | OMIM | HGNC link | 1q21.3 | 1 | 607785 |
ARHGAP26 | ClinVar, OMIM, HUMSAVAR | HGNC link | 5q31.3 | 1 | 607785 |
NF1 | ClinVar, OMIM | HGNC link | 17q11.2 | 5 | 607785, 193520, 162200, 162210, 601321 |
KRAS | ClinVar | HGNC link | 12p12.1 | 14 | 601626, 600268, 137215, 109800, PS163950, 211980, 114480, PS115150, 613659, 163200, 607785, 614470, 162900, 260350 |
Download the disease annotation in CSV format
TF | associated to this disease | # regulated genes | Regulated genes | # regulated genes associated with this disease | Regulated genes associated with this disease |
---|---|---|---|---|---|
SETBP1 | YES | 3 | PTGS2, PTGER2, PPP2R4 | 0 | |
NF1 | YES | 12 | PPP2R2D, SFTPB, GNRH1, TP53, DDB1, AFP, HSD11B2, SP3, PLAT, FOS, MYC, DDB2 | 0 |
regulated gene | associated to this disease | # TFs | TFs | # TFs associated with this disease | TFs associated with this disease |
---|---|---|---|---|---|
NRAS | YES | 1 | AR | 0 | |
NF1 | YES | 12 | SP1, TBPL1, IRF8, GFI1, TBP, YY1, TWIST2, TWIST1, CREB1, CTCF, RUNX1, FOXA1 | 0 | |
KRAS | YES | 1 | MYC | 0 |
Gene1 | Gene2 | Direct Interaction | Number of shared interactors | Shared genes in interaction |
---|---|---|---|---|
SETBP1 | KRAS | No | 1 | APP |
PTPN11 | NRAS | No | 1 | ELAVL1 |
PTPN11 | CBL | Yes | 32 | PTPN11, FLT1, PIK3R2, EGFR, FYN, CRKL, CD33, CRK, STAT5A, PTK2, EPHA2, ERBB2, EPOR, CTNNB1, SOS1, MAPK14, KIT, INPP5D, CBL, CBLB, IL6ST, GRB2, STAT3, FCGR2A, IGF1R, IRS1, PIK3R1, ERBB4, NTRK1, FRS2, PTK2B, BCAR1 |
PTPN11 | ARHGAP26 | No | 1 | PTK2 |
PTPN11 | NF1 | No | 3 | CD274, SLAMF1, CAV1 |
PTPN11 | KRAS | No | 2 | PIK3R2, ELAVL1 |
NRAS | CBL | No | 2 | EEF1A1, CD2AP |
NRAS | KRAS | No | 6 | RGL2, RAP1GDS1, ELAVL1, PIK3CG, RAF1, EEF1A1 |
CBL | ARHGAP26 | No | 3 | CDC42, PTK2, PTEN |
CBL | NF1 | No | 2 | HRAS, YWHAB |
CBL | KRAS | No | 5 | EEF1A1, PIK3R2, CALM1, SORBS3, PIK3CA |
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
Gene1 | Gene2 | Direct Interaction | Number of shared interactors | Shared genes in interaction |
---|---|---|---|---|
NF1 | KRAS | Yes | 1 | KRAS |
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
Gene1 | Gene2 | Direct Interaction | Complexes | Number of shared interactors | Shared genes in interaction |
---|---|---|---|---|---|
PTPN11 | CBL | No | - | 3 | PLCG1, GRB2, PIK3R1 |
NRAS | KRAS | Yes | RAF1-RAS complex, EGF induced | 2 | HRAS, RAF1 |
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
Gene1 | Gene2 | Direct interaction | More information |
---|---|---|---|
KRAS | NRAS | maybe, indirect | They are members of the same protein family. |
KEGG term | KEGG term ID | IC | Number of genes with the same term | Genes |
---|---|---|---|---|
Proteoglycans in cancer | hsa05205 | 5.02 | 4 | PTPN11, KRAS, CBL, NRAS |
Ras signaling pathway | hsa04014 | 4.9 | 4 | PTPN11, KRAS, NF1, NRAS |
Chronic myeloid leukemia | hsa05220 | 6.48 | 4 | PTPN11, KRAS, CBL, NRAS |
Natural killer cell mediated cytotoxicity | hsa04650 | 5.53 | 3 | PTPN11, KRAS, NRAS |
Renal cell carcinoma | hsa05211 | 6.6 | 3 | PTPN11, KRAS, NRAS |
Pathways in cancer | hsa05200 | 3.98 | 3 | CBL, KRAS, NRAS |
T cell receptor signaling pathway | hsa04660 | 6.01 | 3 | CBL, KRAS, NRAS |
Insulin signaling pathway | hsa04910 | 5.55 | 3 | CBL, KRAS, NRAS |
Neurotrophin signaling pathway | hsa04722 | 5.78 | 3 | PTPN11, KRAS, NRAS |
ErbB signaling pathway | hsa04012 | 6.15 | 3 | CBL, KRAS, NRAS |
MAPK signaling pathway | hsa04010 | 4.63 | 3 | NF1, KRAS, NRAS |
Signaling pathways regulating pluripotency of stem cells | hsa04550 | 5.6 | 2 | KRAS, NRAS |
Bladder cancer | hsa05219 | 7.38 | 2 | KRAS, NRAS |
Endometrial cancer | hsa05213 | 6.81 | 2 | KRAS, NRAS |
Thyroid cancer | hsa05216 | 7.48 | 2 | KRAS, NRAS |
Melanoma | hsa05218 | 6.56 | 2 | KRAS, NRAS |
Glioma | hsa05214 | 6.66 | 2 | KRAS, NRAS |
Jak-STAT signaling pathway | hsa04630 | 5.44 | 2 | PTPN11, CBL |
Tight junction | hsa04530 | 5.53 | 2 | KRAS, NRAS |
Long-term potentiation | hsa04720 | 6.64 | 2 | KRAS, NRAS |
Cholinergic synapse | hsa04725 | 5.88 | 2 | KRAS, NRAS |
Choline metabolism in cancer | hsa05231 | 6.09 | 2 | KRAS, NRAS |
FoxO signaling pathway | hsa04068 | 5.63 | 2 | KRAS, NRAS |
Serotonergic synapse | hsa04726 | 5.84 | 2 | KRAS, NRAS |
Chemokine signaling pathway | hsa04062 | 5.19 | 2 | KRAS, NRAS |
Oxytocin signaling pathway | hsa04921 | 5.4 | 2 | KRAS, NRAS |
HTLV-I infection | hsa05166 | 4.59 | 2 | KRAS, NRAS |
Regulation of actin cytoskeleton | hsa04810 | 4.9 | 2 | KRAS, NRAS |
Hepatitis C | hsa05160 | 5.68 | 2 | KRAS, NRAS |
Hepatitis B | hsa05161 | 5.52 | 2 | KRAS, NRAS |
Gap junction | hsa04540 | 6.24 | 2 | KRAS, NRAS |
VEGF signaling pathway | hsa04370 | 6.77 | 2 | KRAS, NRAS |
MicroRNAs in cancer | hsa05206 | 5.38 | 2 | KRAS, NRAS |
Viral carcinogenesis | hsa05203 | 5.08 | 2 | KRAS, NRAS |
GnRH signaling pathway | hsa04912 | 6.18 | 2 | KRAS, NRAS |
B cell receptor signaling pathway | hsa04662 | 6.52 | 2 | KRAS, NRAS |
Non-small cell lung cancer | hsa05223 | 6.88 | 2 | KRAS, NRAS |
Prolactin signaling pathway | hsa04917 | 6.6 | 2 | KRAS, NRAS |
Acute myeloid leukemia | hsa05221 | 6.74 | 2 | KRAS, NRAS |
Estrogen signaling pathway | hsa04915 | 6.11 | 2 | KRAS, NRAS |
Thyroid hormone signaling pathway | hsa04919 | 5.82 | 2 | KRAS, NRAS |
Long-term depression | hsa04730 | 6.74 | 2 | KRAS, NRAS |
PI3K-Akt signaling pathway | hsa04151 | 4.21 | 2 | KRAS, NRAS |
Prostate cancer | hsa05215 | 6.11 | 2 | KRAS, NRAS |
Rap1 signaling pathway | hsa04015 | 4.97 | 2 | KRAS, NRAS |
Melanogenesis | hsa04916 | 5.97 | 2 | KRAS, NRAS |
Alcoholism | hsa05034 | 5.59 | 2 | KRAS, NRAS |
Axon guidance | hsa04360 | 5.63 | 2 | KRAS, NRAS |
Central carbon metabolism in cancer | hsa05230 | 6.7 | 2 | KRAS, NRAS |
Fc epsilon RI signaling pathway | hsa04664 | 6.6 | 2 | KRAS, NRAS |
REACTOME term | REACTOME term ID | IC | Number of genes with the same term | Genes |
---|---|---|---|---|
Signal Transduction | R-HSA-162582 | 1.78 | 6 | PTPN11, NRAS, CBL, ARHGAP26, NF1, KRAS |
Signaling by FGFR | R-HSA-190236 | 4.67 | 5 | PTPN11, KRAS, NF1, NRAS, CBL |
Signaling by Interleukins | R-HSA-449147 | 4.71 | 5 | PTPN11, KRAS, NF1, NRAS, CBL |
Signaling by FGFR1 | R-HSA-5654736 | 4.69 | 5 | PTPN11, KRAS, NF1, NRAS, CBL |
Signaling by FGFR2 | R-HSA-5654738 | 4.68 | 5 | PTPN11, KRAS, NF1, NRAS, CBL |
Immune System | R-HSA-168256 | 2.37 | 5 | PTPN11, KRAS, NF1, NRAS, CBL |
Signaling by SCF-KIT | R-HSA-1433557 | 4.73 | 5 | PTPN11, KRAS, NF1, NRAS, CBL |
Signaling by FGFR4 | R-HSA-5654743 | 4.69 | 5 | PTPN11, KRAS, NF1, NRAS, CBL |
Cytokine Signaling in Immune system | R-HSA-1280215 | 3.74 | 5 | PTPN11, KRAS, NF1, NRAS, CBL |
Interleukin-3, 5 and GM-CSF signaling | R-HSA-512988 | 4.99 | 5 | PTPN11, KRAS, NF1, NRAS, CBL |
Signaling by EGFR | R-HSA-177929 | 4.59 | 5 | PTPN11, KRAS, NF1, CBL, NRAS |
Signaling by FGFR3 | R-HSA-5654741 | 4.69 | 5 | PTPN11, KRAS, NF1, CBL, NRAS |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 4.85 | 4 | PTPN11, KRAS, NF1, NRAS |
Signaling by Leptin | R-HSA-2586552 | 5.1 | 4 | PTPN11, KRAS, NF1, NRAS |
Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 4.62 | 4 | PTPN11, KRAS, CBL, NRAS |
IGF1R signaling cascade | R-HSA-2428924 | 4.85 | 4 | PTPN11, KRAS, NF1, NRAS |
Downstream signal transduction | R-HSA-186763 | 4.65 | 4 | PTPN11, KRAS, NF1, NRAS |
IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.85 | 4 | PTPN11, KRAS, NF1, NRAS |
Signaling by ERBB4 | R-HSA-1236394 | 4.7 | 4 | PTPN11, KRAS, NF1, NRAS |
Signaling by Insulin receptor | R-HSA-74752 | 4.73 | 4 | PTPN11, KRAS, NF1, NRAS |
Adaptive Immune System | R-HSA-1280218 | 3.19 | 4 | PTPN11, KRAS, CBL, NRAS |
Disease | R-HSA-1643685 | 3.33 | 4 | PTPN11, KRAS, CBL, NRAS |
Insulin receptor signalling cascade | R-HSA-74751 | 4.85 | 4 | PTPN11, KRAS, NF1, NRAS |
Downstream signaling of activated FGFR1 | R-HSA-5654687 | 4.71 | 4 | PTPN11, KRAS, NF1, NRAS |
MAPK family signaling cascades | R-HSA-5683057 | 4.89 | 4 | PTPN11, KRAS, NF1, NRAS |
Signalling by NGF | R-HSA-166520 | 4.23 | 4 | PTPN11, KRAS, NF1, NRAS |
MAPK1/MAPK3 signaling | R-HSA-5684996 | 5.11 | 4 | PTPN11, KRAS, NF1, NRAS |
IRS-mediated signalling | R-HSA-112399 | 4.87 | 4 | PTPN11, KRAS, NF1, NRAS |
FRS-mediated FGFR2 signaling | R-HSA-5654700 | 5.14 | 4 | PTPN11, KRAS, NF1, NRAS |
DAP12 interactions | R-HSA-2172127 | 4.56 | 4 | PTPN11, KRAS, NF1, NRAS |
FRS-mediated FGFR3 signaling | R-HSA-5654706 | 5.14 | 4 | PTPN11, KRAS, NF1, NRAS |
Developmental Biology | R-HSA-1266738 | 3.48 | 4 | PTPN11, KRAS, NF1, NRAS |
Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.71 | 4 | PTPN11, KRAS, NF1, NRAS |
Diseases of signal transduction | R-HSA-5663202 | 4.89 | 4 | PTPN11, KRAS, CBL, NRAS |
Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 4.03 | 4 | PTPN11, KRAS, NF1, NRAS |
Innate Immune System | R-HSA-168249 | 3.17 | 4 | PTPN11, KRAS, NF1, NRAS |
Signaling by PDGF | R-HSA-186797 | 4.53 | 4 | PTPN11, KRAS, NF1, NRAS |
DAP12 signaling | R-HSA-2424491 | 4.64 | 4 | PTPN11, KRAS, NF1, NRAS |
Downstream signaling of activated FGFR2 | R-HSA-5654696 | 4.71 | 4 | PTPN11, KRAS, NF1, NRAS |
NGF signalling via TRKA from the plasma membrane | R-HSA-187037 | 4.51 | 4 | PTPN11, KRAS, NF1, NRAS |
FRS-mediated FGFR1 signaling | R-HSA-5654693 | 5.14 | 4 | PTPN11, KRAS, NF1, NRAS |
FRS-mediated FGFR4 signaling | R-HSA-5654712 | 5.14 | 4 | PTPN11, KRAS, NF1, NRAS |
Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.71 | 4 | PTPN11, KRAS, NF1, NRAS |
Signaling by ERBB2 | R-HSA-1227986 | 4.66 | 4 | PTPN11, KRAS, NF1, NRAS |
Axon guidance | R-HSA-422475 | 3.93 | 4 | PTPN11, KRAS, NF1, NRAS |
Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 4.26 | 3 | NF1, KRAS, NRAS |
GRB2 events in ERBB2 signaling | R-HSA-1963640 | 5.15 | 3 | NF1, KRAS, NRAS |
Frs2-mediated activation | R-HSA-170968 | 5.12 | 3 | NF1, KRAS, NRAS |
Cell surface interactions at the vascular wall | R-HSA-202733 | 6.32 | 3 | PTPN11, KRAS, NRAS |
Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 9.08 | 3 | CBL, KRAS, NRAS |
RAF/MAP kinase cascade | R-HSA-5673001 | 5.15 | 3 | NF1, KRAS, NRAS |
Signaling by VEGF | R-HSA-194138 | 4.66 | 3 | NF1, KRAS, NRAS |
Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.12 | 3 | NF1, KRAS, NRAS |
FCERI mediated MAPK activation | R-HSA-2871796 | 4.32 | 3 | NF1, KRAS, NRAS |
Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 8.73 | 3 | CBL, KRAS, NRAS |
Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 9.08 | 3 | CBL, KRAS, NRAS |
Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.59 | 3 | PTPN11, KRAS, NRAS |
Signaling by EGFR in Cancer | R-HSA-1643713 | 8.73 | 3 | CBL, KRAS, NRAS |
VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 4.7 | 3 | NF1, KRAS, NRAS |
Interleukin-2 signaling | R-HSA-451927 | 5.05 | 3 | NF1, KRAS, NRAS |
Interleukin receptor SHC signaling | R-HSA-912526 | 5.09 | 3 | NF1, KRAS, NRAS |
Signalling to ERKs | R-HSA-187687 | 5.04 | 3 | NF1, KRAS, NRAS |
NCAM signaling for neurite out-growth | R-HSA-375165 | 4.9 | 3 | NF1, KRAS, NRAS |
Signalling to RAS | R-HSA-167044 | 5.08 | 3 | NF1, KRAS, NRAS |
SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 8.28 | 3 | PTPN11, KRAS, NRAS |
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 8.73 | 3 | CBL, KRAS, NRAS |
SHC1 events in EGFR signaling | R-HSA-180336 | 5.15 | 3 | NF1, KRAS, NRAS |
Prolonged ERK activation events | R-HSA-169893 | 5.11 | 3 | NF1, KRAS, NRAS |
Regulation of RAS by GAPs | R-HSA-5658442 | 6.92 | 3 | NF1, KRAS, NRAS |
Signaling by GPCR | R-HSA-372790 | 2.68 | 3 | NF1, KRAS, NRAS |
GRB2 events in EGFR signaling | R-HSA-179812 | 5.15 | 3 | NF1, KRAS, NRAS |
SHC1 events in ERBB4 signaling | R-HSA-1250347 | 5.15 | 3 | NF1, KRAS, NRAS |
ARMS-mediated activation | R-HSA-170984 | 5.12 | 3 | NF1, KRAS, NRAS |
SOS-mediated signalling | R-HSA-112412 | 5.15 | 3 | NF1, KRAS, NRAS |
Tie2 Signaling | R-HSA-210993 | 8.81 | 3 | PTPN11, KRAS, NRAS |
SHC1 events in ERBB2 signaling | R-HSA-1250196 | 5.15 | 3 | NF1, KRAS, NRAS |
SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 8.46 | 3 | PTPN11, KRAS, NRAS |
VEGFR2 mediated cell proliferation | R-HSA-5218921 | 5.07 | 3 | NF1, KRAS, NRAS |
Hemostasis | R-HSA-109582 | 3.98 | 3 | PTPN11, KRAS, NRAS |
p38MAPK events | R-HSA-171007 | 9.28 | 2 | KRAS, NRAS |
Signaling by FGFR3 in disease | R-HSA-5655332 | 8.52 | 2 | KRAS, NRAS |
MAP2K and MAPK activation | R-HSA-5674135 | 7.66 | 2 | KRAS, NRAS |
RAF activation | R-HSA-5673000 | 8.34 | 2 | KRAS, NRAS |
SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 8.59 | 2 | KRAS, NRAS |
Negative regulation of FGFR1 signaling | R-HSA-5654726 | 7.98 | 2 | PTPN11, CBL |
Negative regulation of FGFR2 signaling | R-HSA-5654727 | 7.89 | 2 | PTPN11, CBL |
SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 8.81 | 2 | KRAS, NRAS |
Activation of RAS in B cells | R-HSA-1169092 | 10.66 | 2 | KRAS, NRAS |
Signaling by FGFR in disease | R-HSA-1226099 | 7.49 | 2 | KRAS, NRAS |
C-type lectin receptors (CLRs) | R-HSA-5621481 | 6.06 | 2 | KRAS, NRAS |
Spry regulation of FGF signaling | R-HSA-1295596 | 9.18 | 2 | PTPN11, CBL |
Negative regulation of MAPK pathway | R-HSA-5675221 | 7.66 | 2 | KRAS, NRAS |
Signaling by FGFR1 in disease | R-HSA-5655302 | 7.81 | 2 | KRAS, NRAS |
SHC-related events triggered by IGF1R | R-HSA-2428933 | 9.81 | 2 | KRAS, NRAS |
Interleukin-6 signaling | R-HSA-1059683 | 9.52 | 2 | PTPN11, CBL |
Negative regulation of FGFR4 signaling | R-HSA-5654733 | 8.03 | 2 | PTPN11, CBL |
Negative regulation of FGFR3 signaling | R-HSA-5654732 | 8.12 | 2 | PTPN11, CBL |
CD209 (DC-SIGN) signaling | R-HSA-5621575 | 8.59 | 2 | KRAS, NRAS |
Signaling by FGFR4 in disease | R-HSA-5655291 | 9.52 | 2 | KRAS, NRAS |
EGFR Transactivation by Gastrin | R-HSA-2179392 | 9.81 | 2 | KRAS, NRAS |
Signaling by FGFR2 in disease | R-HSA-5655253 | 8.23 | 2 | KRAS, NRAS |
Term | New enriched term | IC | P value | Genes |
---|---|---|---|---|
SH3/SH2 adaptor activity (GO:0005070) | NEW | 5.79 | 0.0 | PTPN11, KRAS, CBL, NRAS |
protein binding, bridging (GO:0030674) | NEW | 4.68 | 0.0 | PTPN11, KRAS, ARHGAP26, NRAS, CBL |
phosphatidylinositol 3-kinase binding (GO:0043548) | NEW | 6.41 | 0.018 | CBL, NRAS |
phosphatidylinositol phospholipase C activity (GO:0004435) | NEW | 6.41 | 0.037 | PTPN11, NRAS |
signaling adaptor activity (GO:0035591) | NEW | 5.43 | 0.0 | PTPN11, KRAS, CBL, NRAS |
phospholipase C activity (GO:0004629) | NEW | 6.3 | 0.041 | PTPN11, NRAS |
enzyme activator activity (GO:0008047) | - | 3.56 | 0.01 | NF1, KRAS, PTPN11, ARHGAP26, CBL |
protein domain specific binding (GO:0019904) | - | 3.32 | 0.006 | PTPN11, KRAS, CBL, ARHGAP26 |
binding, bridging (GO:0060090) | NEW | 4.57 | 0.0 | PTPN11, KRAS, ARHGAP26, NRAS, CBL |
Term | New enriched term | IC | P value | Genes |
---|---|---|---|---|
cytosolic part (GO:0044445) | NEW | 4.34 | 0.046 | PTPN11, CBL, KRAS |
intracellular (GO:0005622) | - | 2.37 | 0.001 | NRAS, CBL, ARHGAP26, NF1, KRAS, MLLT11 |